Glucocorticoids have been universally regarded as anti-inflammatory; however, a considerable number of studies now demonstrate that under some conditions, glucocorticoids are capable of potentiating neuroinflammatory processes (i.e. priming), a permissive function of glucocorticoids. The present review addresses recent evidence that provides insight into the mechanism(s) of glucocorticoid-induced neuroinflammatory priming.
INTRODUCTION
Glucocorticoids are considered, with few exceptions, to be anti-inflammatory [1] . Indeed, exogenous glucocorticoids are highly effective at suppressing inflammatory responses and play an important physiological role in the hypothalamic pituitary adrenal (HPA) response to proinflammatory stimuli (e.g. infection, sterile injury) [2 & ]. However, mounting evidence now suggests that glucocorticoids, in some contexts, may promote or potentiate inflammatory immune responses [3] , findings that have prompted a re-evaluation of the dogma that glucocorticoids are universally anti-inflammatory. The suggestion is that even though elevated glucocorticoids suppress ongoing inflammation through a set of well known mechanisms, they may at the same time potentiate inflammation to subsequent challenges. This evidence comes primarily from studies focused on understanding the mechanisms involved in stress and glucocorticoid-induced priming of neuroinflammatory responses to a subsequent proinflammatory stimulus. Here, we will provide an overview of the conditions under which these phenomena occur, a discussion that will serve as a basis for exploring the mechanistic underpinnings of glucocorticoid potentiation of neuroinflammation.
Central nervous system (CNS) innate immunity and its primary immune effector cell, microglia, are key immunologic substrates for understanding how stress and glucocorticoids potentiate neuroinflammatory responses to proinflammatory challenges. Thus, a brief orientation on neuroinflammation and its main effector cell, microglia, will provide a springboard for examining the role of glucocorticoids in neuroinflammatory priming.
Microglia and neuroinflammation
Innate immunity is the first line of defense against infection. Within the CNS, microglia, as part of the myeloid lineage, constitute the predominant innate immune cell in the brain parenchyma and serve many functions, including immunosurveillance for pathogens, cellular debris, apoptotic cells and alterations in neuronal phenotype [4] . Other macrophage subtypes also serve a critical role in the brain's innate immune response [5] and may contribute to the processes under discussion here. In the healthy CNS, microglia send out processes that sample the local environment at a rate of several times per second [6] and have been termed 'surveillant' [4] . If microglia encounter an infectious agent or cellular debris, the cell undergoes rapid morphological and functional changes that include the synthesis and secretion of inflammatory mediators, including proinflammatory cytokines (e.g. interleukin-1beta, IL-1b), chemokines, nitric oxide, prostaglandins and reactive oxygen species. This response induces neuroinflammation. Of course, most infectious agents do not cross the blood-brain barrier (BBB) and enter the brain. Rather, pathogenic stimuli such as bacteria typically stimulate an innate immune response in the periphery (outside the BBB) resulting in an inflammatory profile quite similar to that observed after microglia directly encounter an infectious agent. However, peripheral inflammatory mediators such as proinflammatory cytokines can induce the de-novo production of proinflammatory cytokines in the brain through several routes of communication connecting peripheral and central innate immune responses. These include both humoral and neural routes of communication (see review by Maier and Watkins [7] ). Notably, proinflammatory cytokines induced in the brain orchestrate a constellation of physiological and behavioural modifications known as the sickness response. This response manifests as cognitive (memory alterations), affective (mood changes), vegetative (sleep and eating disturbances) and physiological (fever) endophenotypes, which play an adaptive role in an organism's host defense against infection, trauma and injury [8] .
Microglia are complex, and it is common to consider whether these cells are activated classically or alternatively, each of which produces cells with different properties. However, recent views suggest that microglia can enter a spectrum of activation states, producing varying blends of proinflammatory and anti-inflammatory products [9] . Of particular relevance here, these cells can enter a state characterized as primed [10] . Primed microglia undergo immunophenotypic changes such as cell surface upregulation of myeloid markers (e.g. major histocompatibility complex II). Primed microglia do not produce inflammatory or anti-inflammatory products but, if further stimulated, produce exaggerated levels of inflammatory products. Interestingly, a primed microglia immunophenotype can also be induced by exposure to stress and glucocorticoids.
Stress and glucocorticoid-induced priming of neuroinflammation
The basic phenomenon of stress and glucocorticoidinduced neuroinflammatory priming involves the following general schema. Initially, an organism is exposed to an acute or chronic stressor, or for that matter exogenous glucocorticoids. After exposure to the stressor, the organism is given a peripheral immune challenge by administering a proinflammatory agent, which induces inflammatory mediators. Typically, the agent consists of lipopolysaccharide (LPS), which is a noninfectious component of gram-negative bacteria (i.e. Escherichia coli) and highly effective at eliciting a proinflammatory response (e.g. IL-1b) in the brain via immuneto-brain communication. Peripheral LPS signals through Toll-like receptor-4 (TLR4) on peripheral
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innate immune cells such as macrophages and microglia in the brain [11] . Signalling through TLR4 induces activation of nuclear factor-kappa light-chain-enhancer of activated B cells (NF-kB), a transcription factor that is critical for proinflammatory cytokine transcription to occur [12] . Usually, LPS is administered at least 24 h after termination of the stressor. Inflammatory mediators are then measured in the brain within hours (2-12) or sometimes days of LPS exposure. The end result is that prior exposure to a stressor potentiates the neuroinflammatory response to the immune challenge, thus indicating that stress induces a primed immunophenotype in the CNS.
Indeed, a considerable number of studies have demonstrated that exposure to acute and chronic stressors shifts the neuroimmune microenvironment towards a microglial activation state that predisposes the CNS to a heightened proinflammatory response (primed) if exposure to a subsequent proinflammatory challenge should occur (reviewed in Frank et al. [13 & ]). Moreover, a subset of these studies found that pharmacological blockade of GC signalling (GR antagonist RU486) prior to or during stress exposure resulted in an attenuation of the stressinduced potentiation of the neuroinflammatory response to an immune challenge. These findings suggest that stress-induced glucocorticoids were necessary for stress-induced priming of the neuroinflammatory response.
These findings raise the key question as to which CNS immune substrate is primed by stress-induced glucocorticoids? Because the above studies administered the immune challenge (LPS) in vivo, it is not possible to determine which cell type(s) was primed by glucocorticoids, as many different types of innate immune cells may contribute to the neuroinflammatory response. To address this question, we conducted a set of studies in which animals were either adrenalectomized (ADX) or administered a glucocorticoid receptor antagonist (RU486) prior to acute stress exposure, with the purpose of suppressing the glucocorticoid response or glucocorticoid signalling due to stress [14 && ]. Twenty-four hours after the stress session ended, hippocampal microglia were isolated and directly challenged with LPS. As noted above, microglia express the receptor for LPS (i.e. TLR4). Here, LPS was used to directly stimulate the microglia proinflammatory response. Importantly, prior stress exposure potentiated the proinflammatory response of microglia to LPS, indicating that stress primes microglia. Furthermore, surgical (ADX) and pharmacological suppression (RU486) of stressinduced glucocorticoids blocked the potentiated proinflammatory response of microglia to LPS. These findings suggest that stress-induced glucocorticoids prime the proinflammatory response of microglia. Similarly, neuroinflammatory priming effects have also been observed by simply administering exogenous glucocorticoids.
Glucocorticoid-induced priming of neuroinflammation
Earlier studies demonstrated that prior exposure to acute or chronic exogenous glucocorticoids also potentiates the neuroinflammatory response to a subsequent immune challenge. In other words, exogenous glucocorticoid exposure was sufficient to replicate the priming effects of stress on microglial and neuroinflammatory responses to an immune challenge. These studies are covered in a recent review by Bellavance and Rivest [2 & ] and will not be addressed here. Here, we will discuss several recent investigations that provide insight into potential mechanisms responsible for glucocorticoid-induced neuroinflammatory priming. An investigation by Kelly et al. [15 && ] assessed the effects of chronic glucocorticoid treatment on the neuroinflammatory effects of methamphetamine (METH). Animals were treated with a high concentration of glucocorticoids administered in their drinking water, which induces many of the immunosuppressive features of highdose glucocorticoids such as thymic involution. On day 7 of glucocorticoid treatment, a proinflammatory dose of METH was administered subcutaneously and neuroinflammatory endpoints measured 12 and 72 h later. Kelly et al. [15 && ] found that prior chronic glucocorticoid exposure potentiated the neuroinflammatory response to METH in a number of brain regions. Moreover, glucocorticoid pretreatment enhanced dopaminergic cell death due to METH treatment in striatum, as measured by tyrosine hydroxylase immuno-staining. Interestingly, similar findings have been reported using a chronic stressor regimen [16 && ]. de Pablos et al. [16 && ] exposed individuals to chronic variable stress for 9 days and were given an intracerebral immune challenge with LPS, rather than METH as above, which was delivered into the substantia nigra. Consistent with prior findings from their laboratory [17] , chronic stress potentiated the neuroinflammatory response to LPS. Interestingly, exposure to chronic stress increased cell death as well as potentiated the LPS-induced cell death of dopaminergic neurons. These effects of chronic stress were blocked by treatment with the glucocorticoid receptor antagonist RU486, suggesting that stressinduced glucocorticoids mediated the neuroinflammatory priming effects as well as the effects of stress on cell death.
It is notable that both Kelly et al. [15 && ] and de Pablos et al. [16 && ] found that stress and/or glucocorticoids potentiated dopaminergic cell death or damage. It is well established that products of dead or damaged cells are capable of inducing inflammation [18] , and so, it is possible that glucocorticoid-induced cell damage may play a pivotal role in the priming effects of stress on neuroinflammation. The notion that cell death or damage can induce an inflammatory response was originally proposed by Matzinger (1994) [19] , who developed the danger model of immunogenicity. This model proposes that the immune system will respond to a stimulus only if that stimulus results in the release of endogenous danger-associated molecular patterns (DAMPs), which signal cellular damage and activate the innate immune system [20] . The danger model is particularly relevant to pathophysiological conditions involving sterile injury or trauma, wherein an inflammatory event is induced in the absence of infection. The damaged tissue and cells then release DAMPs such as high mobility group box-1 (HMGB1) [20] . These DAMPs bind their cognate receptors on innate immune cells such as microglia, thereby inducing neuroinflammatory processes.
The findings above raise the possibility that stress-induced glucocorticoids may damage neurons and other cell types, which then release DAMPs. Subsequently, these molecules may prime microglia and other innate immune cells to proinflammatory agents. Indeed, we found that HMGB1 administered into the cerebrospinal fluid (i.e. intra-cisterna magna, ICM injection) primed the proinflammatory response of microglia [21 && ]. Further, we found that exposure to an acute stressor increased HMGB1 protein levels in the hippocampus immediately after the stress session, as well as 24 h later. In addition, we found that hippocampal microglia, isolated immediately after stress exposure, exhibited increased secretion of HMGB1 compared with control animals.
In light of these effects of stress on HMGB1, it was of interest to determine whether HMGB1 plays a role in stress-induced priming of the microglia proinflammatory response. Towards this aim, an HMGB1 antagonist was injected ICM immediately prior to stress exposure. Microglia were then isolated from the hippocampus 24 h after stress exposure and were challenged with LPS to probe for stress-induced priming. Indeed, blockade of HMGB1 signalling blocked the effect of stress on microglia priming, suggesting that HMGB1 mediates the priming effects of stress on microglia. However, in this study, stress-induced cell death or damage was not assessed, and so, it is unclear whether these processes played a role in neuroinflammatory priming. Nonetheless, taken together, these findings implicate DAMPs as potential mediators of stress and glucocorticoid-induced priming of neuroinflammatory processes. A key question that remains is the mechanism whereby glucocorticoids prime neuroinflammatory processes and the possible role of DAMPs in these processes.
Mechanisms of glucocorticoid priming: the NLRP3 inflammasome
Interestingly, glucocorticoids have been implicated in NLRP3 inflammasome priming [22 & ], which plays a pivotal role in the processing and maturation of the proinflammatory cytokine IL-1b [23] . Inflammasomes are intracellular multiprotein complexes involved in the activation of inflammatory caspases, which mediate the processing and maturation of proinflammatory cytokines. Importantly, the NLRP3 inflammasome is a sensor for a diverse array of DAMPs, including HMGB1, which have been implicated in the pathophysiology of sterile inflammatory diseases [24] . Formation and activation of the NLRP3 inflammasome requires both a priming step and a second activation step [25] . Priming of the NLRP3 inflammasome is induced by a stimulus that signals, in part, through TLR4 to increase NLRP3 expression to a critical level necessary for inflammasome formation. Of note, the DAMP HMGB1 exerts its proinflammatory effects through TLR4 [26] . If the inflammasome is then exposed to a subsequent activating signal, the primed increase in NLRP3 permits formation of a molecular complex with the adaptor apoptosis-associated speck-like protein (ASC), which recruits and cleaves procaspase-1 to mature caspase-1. Finally, caspase-1 converts pro-IL-1b to the mature and active form of IL-1b, which is released into the extracellular space.
Intriguingly, Busillo et al. [27 && ] found that glucocorticoids increase NLRP3 mRNA and protein in macrophages without inducing a proinflammatory response, an effect mediated by the glucocorticoid receptor. If glucocorticoid-exposed macrophages were subsequently challenged with the NLRP3 inflammasome-activating stimulus ATP, the proinflammatory response to ATP was amplified suggesting that glucocorticoids primed macrophages by increasing expression of NLRP3. We have also found that glucocorticoid treatment of isolated microglia increases NLRP3 expression (unpublished observations). Moreover, we found similar results with chronic glucocorticoid exposure [28 && ]. Animals were treated with varying concentrations of glucocorticoids in drinking water for 10 days. The high glucocorticoid treatment condition potentiated the microglia proinflammatory response to LPS. Further, high glucocorticoid treatment increased expression of NLRP3 in the hippocampus and potentiated the LPS induction of NLRP3 in microglia.
In light of these findings that glucocorticoids prime the NLRP3 inflammasome, we propose that glucocorticoid priming of neuroinflammatory processes is mediated, in part, through priming of the NLRP3 inflammasome. Thus, if an organism is subsequently challenged with a proinflammatory stimulus (i.e. LPS), the NLRP3 inflammasome is activated resulting in a potentiated proinflammatory cytokine response. Finally, two lines of evidence converge to suggest that DAMPs such as HMGB1 may mediate glucocorticoid-induced priming of the NLRP3 inflammasome. First, the proinflammatory effects of HMGB1 are mediated, in part, through TLR4, and second, the NLRP3 inflammasome is also primed through TLR4. Therefore, the following scenario of glucocorticoid-induced neuroinflammatory priming is suggested (Fig. 1) . During exposure to a stressor or exogenous glucocorticoids, glucocorticoids via the glucocorticoid receptor induce the release of HMGB1 within the brain. HMGB1 may be actively released from innate immune cells (microglia) or passively released from damaged or stressed neurons. HMGB1 then signals through TLR4 on microglia to prime the NLRP3 inflammasome by increasing NLRP3 protein levels to a critical threshold. This results in a primed neuroinflammatory state. If a subsequent immune challenge occurs, the NLRP3 inflammasome is activated resulting in a potentiated proinflammatory cytokine response. This mechanism of priming may help explain the paradoxical effects of glucocorticoids in some clinical conditions, in which glucocorticoids potentiate, rather than suppress proinflammatory processes.
CONCLUSION
From an adaptive point of view, it has always seemed mysterious as to why glucocorticoids should Primed: If an organism is exposed to stress or exogenous GCs, GC levels in the brain are increased resulting in a cascade of cellular events. First, GCs ligate the low affinity GR located on multiple cell types including neurons and microglia. Second, ligation of the GR on neurons results in cellular stress or damage and the passive release of the DAMP HMGB1, while ligation of the GR on microglia leads to the active secretion of HMGB1. Third, extracellular HMGB1 binds TLR4 leading to increased NLRP3 mRNA and protein. Activated: If an organism is subsequently exposed to a proinflammatory immune challenge (LPS), the NLRP3 inflammasome is activated resulting in activation of caspase-1, which cleaves pro-IL-1 to mature IL-1. IL-1 is then released to induce a cascade of proinflammatory events resulting in neuroinflammation. DAMP, damage-associated molecular pattern; GC, glucocorticoid; GR, glucocorticoid receptor; HMGB1, high mobility group box-1; IL-1, interleukin-1; LPS, lipopolysaccharide; NLRP3, nucleotide-binding domain, leucine-rich repeat, pyrin domain containing proteins-3; TLR, Toll-like receptor.
inhibit innate immune responses, as the likelihood of infection and injury should increase during a flight-or-flight emergency. Perhaps during such an emergency, available energy stores should be diverted to defensive behaviours, and it might be after the emergency is over that resources should be shifted to recuperation and host defense against infection. This is the scenario that would be promoted by elevated glucocorticoids reducing ongoing inflammation while simultaneously priming the NLRP3 inflammasome.
